Development
Vera Therapeutics, Inc.
VERA
$20.64
$0.190.93%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.45M | 24.38M | 23.59M | 21.91M | 18.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 108.57M | 112.05M | 105.14M | 90.90M | 73.91M |
| Operating Income | -108.57M | -112.05M | -105.14M | -90.90M | -73.91M |
| Income Before Tax | -102.77M | -107.35M | -102.04M | -89.06M | -73.46M |
| Income Tax Expenses | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Earnings from Continuing Operations | -102.77 | -107.35 | -102.04 | -89.06 | -73.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.77M | -107.35M | -102.04M | -89.06M | -73.46M |
| EBIT | -108.57M | -112.05M | -105.14M | -90.90M | -73.91M |
| EBITDA | -33.54M | -58.74M | -73.79M | -90.80M | -73.81M |
| EPS Basic | -2.88 | -3.33 | -3.42 | -3.33 | -2.95 |
| Normalized Basic EPS | -1.80 | -2.08 | -2.13 | -2.06 | -1.82 |
| EPS Diluted | -2.88 | -3.33 | -3.42 | -3.33 | -2.95 |
| Normalized Diluted EPS | -1.80 | -2.08 | -2.13 | -2.06 | -1.82 |
| Average Basic Shares Outstanding | 154.03M | 136.88M | 119.69M | 106.25M | 99.80M |
| Average Diluted Shares Outstanding | 154.03M | 136.88M | 119.69M | 106.25M | 99.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |